Proinflammatory cytokines block growth of breast cancer cells by impairing signals from a growth factor receptor

Cancer Research

Volumn 62, Issue 16, 2002, Pages 4746-4756

  Shen, Wen Hong ^a   Zhou, Jian Hua ^a   Broussard, Suzanne R ^a   Freund, Gregory G ^a   Dantzer, Robert ^a   Kelley, Keith W ^a  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; DNA FRAGMENT; GROWTH FACTOR RECEPTOR; INSULIN RECEPTOR SUBSTRATE 1; INTERLEUKIN 1BETA; INTERLEUKIN 6; SOMATOMEDIN C RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; TYROSINE KINASE RECEPTOR;

ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER IMMUNOLOGY; CANCER INHIBITION; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL STRAIN MCF 7; CELL TRANSFORMATION; CONTROLLED STUDY; DNA DEGRADATION; DNA SYNTHESIS; EPITHELIUM CELL; FLOW CYTOMETRY; HUMAN; HUMAN CELL; INFLAMMATION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

ADENOCARCINOMA; APOPTOSIS; BREAST NEOPLASMS; CELL CYCLE; CELL DIVISION; DNA, NEOPLASM; HUMANS; INSULIN-LIKE GROWTH FACTOR I; INTERLEUKIN-1; INTERLEUKIN-6; PHOSPHOPROTEINS; PHOSPHORYLATION; RECEPTOR, IGF TYPE 1; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA; TYROSINE;

EID: 0037102303     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (82)

1. A new method of antitumor therapy with a high dose of TNF perfusion for unresectable liver tumors
2. A phase I trial of recombinant human interleukin-I β (OCT-43) following high-dose chemotherapy and autologous bone marrow transplantation
3. A phase I clinical, pharmacological, and biological trial of interleukin 6 plus granulocyte-colony stimulating factor after ifosfamide, carboplatin, and etoposide in children with recurrent/refractory solid tumors: Enhanced hematological responses but a high incidence of grade III/IV constitutional toxicities
4. Circulating concentrations of insulinlike growth factor-I and risk of breast cancer
5. Plasma insulin-like growth factor-I and prostate cancer risk: A prospective study
6. High-risk colorectal adenomas and serum insulin-like growth factors
7. Insulin-like growth factor physiology and cancer risk
8. Role of the insulin-like growth factor family in cancer development and progression
9. Growth hormone treatment induces mammary gland hyperplasia in aging primates
10. Growth factors, apoptosis, and survival of mammary epithelial cells
11. Insulin/insulin-like growth factor-I and estrogen cooperate to stimulate cyclin E-cdk2 activation and cell cycle progression in MCF-7 breast cancer cells through differential regulation of cyclin E and p21WAF1/Cipl
12. Cytostatic and cytotoxic effects of tumor necrosis factor α on MCF-7 human breast tumor cells are differently inhibited by glucocorticoid hormones
13. Tumour necrosis factor and interferon are selectively cytostatic in vitro for hormone-dependent and hormone-independent human breast cancer cells
14. IL-4 and insulin-like growth factor I inhibit the decline in Bcl-2 and promote the survival of IL-3-deprived myeloid progenitors
15. Regulation of myeloid growth and differentiation by the insulin-like growth factor I receptor
16. Activation of phosphatidylinositol 3′-kinase by insulin-like growth factor-I rescues promyeloid cells from apoptosis and permits their differentiation into granulocytes
17. Insulin-like growth factor-I receptor antagonism results in increased cytotoxicity of breast cancer cells to doxorubicin and taxol
18. Insulin-like growth factor I receptor antagonism augments response to chemoradiation therapy in colon cancer cells
19. Activation of integrin and ceramide signalling pathways can inhibit the mitogenic effect of insulin-like growth factor I (IGF-I) in human breast cancer cell lines
20. Requirement for phosphatidylinositol 3′-kinase to protect hemopoietic progenitors against apoptosis depends upon the extracellular survival factor
21. Morphological, biochemical, and flow cytometric assays of apoptosis
22. Insulin-like growth factor I and oestradiol promote cell proliferation of MCF-7 breast cancer cells: New insights into their synergistic effects
23. Dexamethasone inhibits TNF-α-induced apoptosis and IAP protein downregulation in MCF-7 cells
24. Interactions of vitamin D analogue CB1093. TNFα and ceramide on breast cancer cell apoptosis
25. Interleukin-1 α and interleukin-6 act additively to inhibit growth of MCF-7 breast cancer cells in vitro
26. Interleukin-1 blocks insulin and insulin-like growth factor-stimulated growth in MCF-7 human breast cancer cells by inhibiting receptor tyrosine kinase activity
27. Interleukin-1 α and tumor necrosis factor-α (TNF α) inhibit growth and induce TNF messenger RNA in MCF-7 human breast cancer cells
28. Growth factors and cancer
29. Regulation of Id2 gene expression by the insulin-like growth factor I receptor requires signaling by phosphatidylinositol 3-kinase
30. Regulation of Id gene expression by type I insulin-like growth factor: Roles of Stat3 and the tyrosine 950 residue of the receptor
31. Regulation of Id2 gene expression by the type 1 IGF receptor and the insulin receptor substrate-1
32. The proliferative and antiapoptotic actions of growth hormone and insulin-like growth factor-I are mediated through distinct signaling pathways in the Pro-B Ba/F3 cell line
33. Cooperative regulation of the invasive and metastatic phenotypes by different domains of the type I insulin-like growth factor receptor β subunit
34. TGF-α IGF-I effects on calcium ion transients in human breast cancer cells
35. Insulin receptor substrate-1 is the predominant signaling molecule activated by insulin-like growth factor-I, insulin, and interleukin-4 in estrogen receptor-positive human breast cancer cells
36. Activation of the insulin-like growth factor I signaling pathway by the antiapoptotic agents aurintricarboxylic acid and evans blue
37. Adenovirus-mcdiated TNF-α gene transfer induces significant tumor regression in mice
38. Tumor necrosis factor induces tumor necrosis via tumor necrosis factor receptor type 1-expressing endothelial cells of the tumor vasculature
39. Role of the IGF-I receptor in mutagenesis and tumor promotion
40. The IGF-I receptor in cancer research
41. IGF-I receptor signaling in transformation and differentiation
42. Mechanisms of regulation of cell adhesion and motility by insulin receptor substrate-1 in prostate cancer cells
43. Phosphatidylinositol 3′-kinase, but not S6-kinase, is required for insulin-like growth factor-I and IL-4 to maintain expression of Bcl-2 and promote survival of myeloid progenitors
44. IL-10 inhibits apoptosis of promyeloid cells by activating insulin receptor substrate-2 and phosphatidylinositol 3′-kinase
45. 3 and immune cytokines: The involvement of reactive oxygen species
46. Overexpression of manganese superoxide dismutase suppresses tumor necrosis factor-induced apoptosis and activation of nuclear transcription factor-KB and activated protein-1
47. P13-K/AKT regulation of NF-κB signaling events in suppression of TNF-induced apoptosis
48. Induction of inducible nitric oxide synthase is an essential part of tumor necrosis factor-α-induced apoptosis in MCF-7 and other epithelial tumor cells
49. JNK and p53 stress signaling cascades are altered in MCF-7 cells resistant to tumor necrosis factor-mediated apoptosis
50. Apoptotic and non-apoptotic modes of programmed cell death in MCF-7 human breast carcinoma cells
51. Cross-talk between phosphatidylinositol 3-kinase and sphingomyelinase pathways as a mechanism for cell survival/death decisions
52. Interaction of vitamin D analogs with signaling pathways leading to active cell death in breast cancer cells
53. Role of defined and undefined serum additives to hematopoietic stem cell culture
54. Overexpression of the LAR (leukocyte antigen-related) protein-tyrosine phosphatase in muscle causes insulin resistance
55. Release of insulin receptor substrate proteins from an intracellular complex coincides with the development of insulin resistance
56. A rapamycin-sensitive pathway down-regulates insulin signaling via phosphorylation and proteasomal degradation of insulin receptor substrate-1
57. Phosphorylation of Ser307 in insulin receptor substrate-1 blocks interactions with the insulin receptor and inhibits insulin action
58. Serine/threonine phosphorylation of IRS-1 triggers its degradation: Possible regulation by tyrosine phosphorylation
59. Insulin receptor substrate 1 translocation to the nucleus by the human JC virus T-antigen
60. Tumor necrosis factor α-induced phosphorylation of insulin receptor substrate-1 (IRS-1) Possible mechanism for suppression of insulin-stimulated tyrosine phosphorylation of IRS-1
61. Phosphorylation of insulin receptor substrate-1 (IRS-1) by protein kinase B positively regulates IRS-1 function
62. Insulin/IGF-1 and TNF-α stimulate phosphorylation of IRS-1 at inhibitory Ser307 via distinct pathways
63. Mutation of the insulin receptor at tyrosine 960 inhibits signal transmission but does not affect its tyrosine kinase activity
64. The IRS-signaling system: A network of docking proteins that mediate insulin and cytokine action
65. The IRS-signalling system during insulin and cytokine action
66. Non-SH2 domains within insulin receptor substrate-1 and SHC mediate their phosphotyrosine-dependent interaction with the NPEY motif of the insulin-like growth factor I receptor
67. Evidence for the direct interaction of the insulin-like growth factor I receptor with IRS-1, Shc, and Grb10
68. Evidence for a differential interaction of SHC and the insulin receptor substrate-1 (IRS-1) with the insulin-like growth factor-I (IGF-I) receptor in the yeast two-hybrid system
69. TNF registered in Europe: Does TNF get a second chance?
70. Contribution of cytokines on the suppression of lung metastasis
71. The host environment promotes the constitutive activation of nuclear factor-κB and proinflammatory cytokine expression during metastatic tumor progression of murine squamous cell carcinoma
72. Tumor necrosis factor α sensitizes low epidermal growth factor receptor (EGFR)-expressing carcinomas for anti-EGFR therapy
73. Combinational immunotherapy for established tumors with engineered tumor vaccines and adenovirus-mediated gene transfer
74. Novel mutein of tumor necrosis factor α (F4614) with reduced hypotensive effect
75. Overcoming the metastasis-enhancing potential of human tumor necrosis factor α by introducing the cell-adhesive Arg-Gly-Asp sequence
76. Human tumor necrosis factor-α mutant RGD-V29 (F4614) shows potent antitumor activity and reduced toxicity against human tumor xenografted nude mice
77. neu to inhibit mammary carcinogenesis in Her-2/neu transgenic BALB/c mice
78. Increasing the immunogenicity of protein antigens through the genetic insertion of VQGEESNDK sequence of human IL-1 β into their sequence
79. Isolated hepatic perfusion with tumor necrosis factor and melphalan for unresectable cancers confined to the liver
80. Construction and expression in tumor cells of a recombinant vaccinia virus encoding human interleukin-1 β
81. An apoptosis-inducing gene therapy for pancreatic cancer with a combination of 55-kDa tumor necrosis factor (TNF) receptor gene transfection and mutein TNF administration